Study #2020-0153
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
MD Anderson Study Status
Enrolling
Treatment Agent
BCA101, Pembrolizumab
Description
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Study phase:
Phase I
Physician name:
Van Morris
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-419-2881
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.